Previous Article | Next Article ![]()
Journal of Clinical Microbiology, September 2007, p. 3138-3140, Vol. 45, No. 9
0095-1137/07/$08.00+0 doi:10.1128/JCM.00021-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
| CASE REPORT |

Service des Maladies Infectieuses, Hôpital de la Conception,1 Laboratoire de Parasitologie-Mycologie,2 Laboratoire dAnatomopathologie,6 Hôpital Timone, and Département dAnesthésie-Réanimation, Hôpital Sainte Marguerite,4 Marseille, and Faculté de Médecine, EA3174,5 Centre National Référence de la Toxoplasmose, Limoges, France3
Received 4 January 2007/ Returned for modification 12 March 2007/ Accepted 2 July 2007
|
|
|---|
|
|
|---|
Empirical treatment with sulfadiazine (6 g/day), pyrimethamine (100 mg/day), and voriconazole (400 mg/day) in association with a glucocorticoid (methylprednisolone at 1 mg/kg of body weight/day) was started the day after the brain MRI. A brain biopsy was performed 2 days later because of the severe neurological symptoms and the atypical MRI images of the cerebral lesions. Histological examination of the brain biopsy sample showed areas of coagulative necrosis surrounded by chronic inflammation. There were free and May-Grünwald-Giemsa- and periodic acid-Schiff-stained intracellular tachyzoites and cysts filled with ovoid bradyzoites suggestive of Toxoplasma gondii (Fig. 1). Real-time PCR targeting a repetitive 529-bp DNA fragment of T. gondii (GenBank accession no. AF487550) in both the brain biopsy and CSF samples was positive. The number of T. gondii tachyzoites was estimated to be 1,000/ml of CSF. Direct genetic characterization of five microsatellite loci (TUB2, TgM-A, W35, B17, and B18) of the organisms in the brain biopsy sample was done in a multiplex PCR assay and revealed a mixture of type I and type III alleles (1). The serological tests for T. gondii showed high immunoglobulin G levels (858 UI/ml) with no detectable immunoglobulin M. Bacterial, fungal, and viral cultures of CSF were negative. A real-time panfungal PCR assay and mycological cultures of the CSF and brain biopsy samples were negative. Five days after admission into the intensive care unit, the patient had acute hyponatremia (sodium concentration, 130 mmol/liter of plasma) associated with decreased central venous pressure and increased daily urine output (4.52 liters). There was massive natriuresis (114 mmol of sodium/liter) with elevated urine osmolality (414 mmol/liter). Serum osmolality and the blood urea nitrogen level were normal. Cerebral salt wasting syndrome was diagnosed based on intracranial lesions, hyponatremia with polyuria, and natriuresis. After 6 days of water and electrolyte replacement, plasma and urinary electrolyte levels returned to the normal ranges. The cerebral lesions markedly improved as demonstrated by the computed tomography scan. Persistent pancytopenia and cholestasis prompted a bone marrow analysis that showed a hemophagocytic syndrome and macrophages containing intracytoplasmic budding yeasts stained with May-Grünwald-Giemsa stain. These features and the size of the organisms suggested the presence of Histoplasma capsulatum. The Histoplasma antigen detection test is not available in France and was not done. A real-time panfungal PCR assay of a bone marrow sample was positive. The diagnosis of disseminated histoplasmosis was confirmed 7 days later by bone marrow culture at 25°C on Novy-MacNeal-Nicolle culture medium (intended to grow Leishmania sp.) and later on Sabouraud dextrose agar. Tests for the detection of antibody against Histoplasma and blood cultures remained negative. Voriconazole (400 mg/day), which was administrated for 2 weeks because of the repetitively elevated Platelia Aspergillus indexes, was switched to intravenous liposomal amphotericin B (4 mg/kg/day) for 20 days, followed by oral itraconazole (200 mg/day). After 4 weeks, the patient recovered from Toxoplasma encephalitis and disseminated histoplasmosis. Transaminase levels and platelet and leukocyte counts normalized within 4 weeks. The Platelia Aspergillus indexes normalized after 2 months. Both antitoxoplasmic and antifungal treatments were sustained. Highly active antiretroviral therapy, including emtricitabine, tenofovir, and efavirenz, was initiated. Despite a persistently low (
14/mm3) CD4 lymphocyte count, there was no evidence of a relapse of either toxoplasmosis or histoplasmosis. After 5 months of follow-up, the patient died from septic shock complicating Pseudomonas aeruginosa pneumonia.
![]() View larger version (136K): [in a new window] |
FIG. 1. Histology of the patient's brain biopsy sample. (A) T. gondii cyst (stained with hematoxylin and eosin). (B) Extracellular T. gondii tachyzoites (stained with hematoxylin and eosin). (C and D) May-Grünwald-Giemsa (C)- and periodic acid-Schiff (D)-stained T. gondii tachyzoites within macrophages. Original magnification, x1,000.
|
The majority of T. gondii strains isolated in Europe and the United States cluster within the three main clonal genotypes: I, II, and III. Several studies have suggested a link between disease severity and Toxoplasma strains (8). Type I strains have been associated with high-level virulence in mice (11). They have the ability to cross epithelial barriers rapidly and reach immunoprivileged sites (4). An overrepresentation of type I strains in patients with ocular toxoplasmosis (6) and in immunocompromised patients (8) in some studies with limited sampling has been described previously. Type II strains, avirulent in mice, are the most prevalent in patients with toxoplasmosis and in immunocompromised patients as well as those with congenital toxoplasmosis (2, 7, 8) in Europe and the United States. Type III strains have occasionally been described in association with human toxoplasmosis (2, 7) but are very uncommon, at least in Europe and the United States. The genetic characterization of our patient's isolate yielded an unusual combination of type I and III alleles, which has been found in other African patients (3). At least in mice, new combinations of alleles can lead to a dramatic increase in virulence (10). Atypical and/or recombinant genotypes are found more frequently among isolates from exotic host species, geographically remote areas, and patients with severe disease (3). These genotypes have been associated with severe toxoplasmosis acquired by immunocompetent patients in French Guiana (5), human ocular toxoplasmosis (6), and severe forms of congenital toxoplasmosis (2).
The unusually severe encephalitis and chorioretinitis associated with the reactivation of a T. gondii genotype I/III strain in an immunocompromised patient fuels the hypothesis of strain-related differences in the virulence of T. gondii parasites and opens new avenues of research to illuminate this fascinating aspect of host-parasite interactions.
Published ahead of print on 18 July 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»